ABOUT US​

​

Launched in March 2020 out of a partnership between LifeMax and Amgen, AmMax Bio, Inc. (“AmMax”) is a privately held, clinical stage biotech company focused on unlocking the therapeutic potential of the CSF1R platform (“colony stimulating factor 1 receptor”) to address diseases with significant unmet medical needs and sizable market potential. We have two clinical stage programs ready to enter Phase 2 studies.

R&D

​

AmMax has established a robust pipeline targeting CSF1R. In addition to tenosynovial giant cell tumor wherein an overexpression of CSF1 drives the pathogenesis, AmMax’s pipeline addresses a number of other diseases with critical unmet medical needs, such as idiopathic pulmonary fibrosis and polycystic kidney diseases, by leveraging the anti-inflammatory, anti-fibrotic and anti-neovascular technology platform targeting CSF1R.

May 26, 2021 

AmMax Bio Announces First Patient Enrolled in Phase 2 Trial of...

REDWOOD CITY, Calif. May 26, 2021 — AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing novel treatments with AMB-05X, its proprietary...

​